Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Cornea. 2011 Jan;30(1):60-6. doi: 10.1097/ICO.0b013e3181e458c5.
To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy.
A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests.
After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects.
The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.
观察玻璃体内注射贝伐单抗治疗伴有脂质沉积的角膜新生血管（NV）的效果。
本病例干预研究纳入了 18 例（18 只眼）伴有脂质沉积的角膜新生血管患者。根据临床反应，在随访期间每月进行 3 至 10 次玻璃体内注射贝伐单抗。评估角膜 NV 的中心性、范围和受累角膜表面百分比（PICS）；角膜脂质沉积的密度和 PICS；以及治疗前后的最佳矫正视力。采用 Wilcoxon 和学生 t 检验分析治疗效果。
治疗后最佳矫正视力的变化小于 2 行。治疗后角膜 NV 的范围、中心性和 PICS 以及角膜脂质沉积的密度和 PICS 均显著降低（P = 0.014/0.002/0.001 和 0.001/<0.001）。所有患者均未出现不良反应。
玻璃体内注射贝伐单抗治疗伴有脂质沉积的角膜 NV 具有一定效果。
